Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M2 and M4 receptors

Molecular Pharmacology

Volumn 86, Issue 1, 2014, Pages 106-115

  Croy, Carrie H ^a   Schober, Douglas A ^a   Xiao, Hongling ^a   Quets, Anne ^a   Christopoulos, Arthur ^b   Felder, Christian C ^a  

^a ELI LILLY AND COMPANY   (United States)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 5 CHLORO N CYCLOPROPYL 4 METHYL 6 [2 (4 METHYLPIPERAZIN 1 YL) 2 OXOETHOXY]THIENO[2,3 B]PYRIDINE 2 CARBOXAMIDE; G PROTEIN COUPLED RECEPTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); GUANOSINE TRIPHOSPHATE; MUSCARINIC AGENT; MUSCARINIC M2 RECEPTOR; MUSCARINIC M4 RECEPTOR; OXOTREMORINE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND; OXOTREMORINE M;

ALLOSTERISM; ANIMAL CELL; ARTICLE; COMPETITIVE BINDING ASSAY; CROSS REACTION; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; GTPGAMMAS BINDING ASSAY; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; BINDING SITE; CELL LINE; CHO CELL LINE; CRICETULUS; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM; PHYSIOLOGY;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; CELL LINE; CHO CELLS; CRICETULUS; GTP-BINDING PROTEINS; HUMANS; LIGANDS; MUSCARINIC AGONISTS; OXOTREMORINE; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M4; SIGNAL TRANSDUCTION;

EID: 84903552336     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.091751     Document Type: Article

References (44)

1. Bock A, Merten N, Schrage R, Dallanoce C, Bätz J, Klöckner J, Schmitz J, Matera C, Simon K, and Kebig A et al. (2012) The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling. Nat Commun 3:1044.
2. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, and Bymaster FP et al. (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54:465-473.
3. Brady AE, Jones CK, Bridges TM, Kennedy JP, Thompson AD, Heiman JU, Breininger ML, Gentry PR, Yin H, and Jadhav SB et al. (2008) Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther 327:941-953.
4. Bridges TM, Marlo JE, Niswender CM, Jones CK, Jadhav SB, Gentry PR, Plumley HC, Weaver CD, Conn PJ, and Lindsley CW (2009) Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins. J Med Chem 52:3445-3448.
5. Bridges TM, Niswender CM, Jones CK, Lewis LM, Weaver CD, Wood MR, Daniels JS, Conn PJ, and Lindsley CW (2010) Discovery of a highly selective in vitro and in vivo M4 positive allosteric modulator (PAM), in Series with Greatly Improved Human Receptor Activity. Probe Reports from the NIH Molecular Libraries Program, Bethesda, MD.
6. Bymaster FP, Felder C, Ahmed S, and McKinzie D (2002) Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Targets CNS Neurol Disord 1:163-181.
7. Chan WY, Broad LM, Lazareno S, Birdsall NJ, Bose S, Mitchell SN, Large T, Emkey R, Sher E, Thompson RC et al. (2004) Pharmacological and molecular characterization of a positive allosteric modulator selective for muscarinic M4 receptor; Society for Neuroscience; 2004 Oct. 23-27; San Diego, CA.
8. Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christopoulos A, Lazareno S, Birdsall NJ, and Bymaster FP et al. (2008) Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci USA 105:10978-10983.
9. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
10. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
11. Dallanoce C, Conti P, De Amici M, De Micheli C, Barocelli E, Chiavarini M, Ballabeni V, Bertoni S, and Impicciatore M (1999) Synthesis and functional characterization of novel derivatives related to oxotremorine and oxotremorine-M. Bioorg Med Chem 7:1539-1547.
12. Daval SB, Kellenberger E, Bonnet D, Utard V, Galzi JL, and Ilien B (2013) Exploration of the orthosteric/allosteric interface in human M1 muscarinic receptors by bitopic fluorescent ligands. Mol Pharmacol 84:71-85.
13. DeLapp NW, McKinzie JH, Sawyer BD, Vandergriff A, Falcone J, McClure D, and Felder CC (1999) Determination of [35S]guanosine-5′-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay. J Pharmacol Exp Ther 289:946-955.
14. 4 muscarinic acetylcholine receptor function inhibits behavioral and neurochemical effects of cocaine. Psychopharmacology 224:277-287.
15. Felder CC, McKinzie DL, Thompson RC, and Liu BL (2012) Muscarinic acetylcholine receptors as novel targets for the development of therapeutics for schizophrenia, in Targets and Emerging Therapies for Schizophrenia (Albert JS ed), pp 355-423, Wiley, New York.
16. 4 receptors, enhances inhibition by oxotremorine of light-induced phase shifts in hamster circadian activity rhythms. Psychopharmacology 224:231-240.
17. Gregory KJ, Hall NE, Tobin AB, Sexton PM, and Christopoulos A (2010) Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J Biol Chem 285:7459-7474.
18. Huang XP, Prilla S, Mohr K, and Ellis J (2005) Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine receptor: more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide. Mol Pharmacol 68:769-778.
19. Huynh T, Valant C, Crosby IT, Sexton PM, Christopoulos A, and Capuano B (2013) Probing structural requirements of positive allosteric modulators of the M4 muscarinic receptor. J Med Chem 56:8196-8200.
20. Jones CK, Byun N, and Bubser M (2012) Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 37:16-42.
21. Kenakin T (2007) Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol 72:1393-1401.
22. Kloeckner J, Schmitz J, and Holzgrabe U (2010) Convergent, short synthesis of the muscarinic superagonist iperoxo. Tetrahedron Lett 51:3470-3472.
23. Kruse AC, Ring AM, Manglik A, Hu J, Hu K, Eitel K, Hübner H, Pardon E, Valant C, and Sexton PM et al. (2013) Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504:101-106.
24. Langmead CJ and Christopoulos A (2013) Supra-physiological efficacy at GPCRs: superstition or super agonists? Br J Pharmacol 169:353-356.
25. Le U, Melancon BJ, Bridges TM, Vinson PN, Utley TJ, Lamsal A, Rodriguez AL, Venable D, Sheffler DJ, and Jones CK et al. (2013) Discovery of a selective M? positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia. Bioorg Med Chem Lett 23:346-350.
26. Leach K, Davey AE, Felder CC, Sexton PM, and Christopoulos A (2011) The role of transmembrane domain 3 in the actions of orthosteric, allosteric, and atypical agonists of the M4 muscarinic acetylcholine receptor. Mol Pharmacol 79:855-865.
27. Leach K, Loiacono RE, Felder CC, McKinzie DL, Mogg A, Shaw DB, Sexton PM, and Christopoulos A (2010) Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 35:855-869.
28. Lewis LM, Bridges TM, Niswender CM, Weaver CD, and Lindsley CW (2010) Discovery of a Highly Selective In Vitro and In Vivo M4 Positive Allosteric Modulator (PAM), Probe Reports from the NIH Molecular Libraries Program, Bethesda, MD.
29. Luttrell LM and Kenakin TP (2011) Refining efficacy: allosterism and bias in G protein-coupled receptor signaling. Methods Mol Biol 756:3-35.
30. McKinzie DL and Bymaster FP (2012) Muscarinic mechanisms in psychotic disorders. Handb Exp Pharmacol 213:233-265.
31. Nawaratne V, Leach K, Felder CC, Sexton PM, and Christopoulos A (2010) Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. J Biol Chem 285:19012-19021.
32. Nawaratne V, Leach K, Suratman N, Loiacono RE, Felder CC, Armbruster BN, Roth BL, Sexton PM, and Christopoulos A (2008) New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Mol Pharmacol 74:1119-1131.
33. 4 muscarinic receptor. WO 2006/047124 A1. 2006 May 4.
34. Salovich JM, Vinson PN, Sheffler DJ, Lamsal A, Utley TJ, Blobaum AL, Bridges TM, Le U, Jones CK, and Wood MR et al. (2012) Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor. Bioorg Med Chem Lett 22:5084-5088.
35. 4 muscarinic receptor allosteric binding sites. Mol Pharmacol 86:116-123.
36. Schrage R, Seemann WK, Klöckner J, Dallanoce C, Racké K, Kostenis E, De Amici M, Holzgrabe U, and Mohr K (2013) Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor. Br J Pharmacol 169:357-370.
37. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, and Felder CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165:1033-1039.
38. Shirey JK, Xiang Z, Orton D, Brady AE, Johnson KA, Williams R, Ayala JE, Rodriguez AL, Wess J, and Weaver D et al. (2008) An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol 4:42-50.
39. Suratman S, Leach K, Sexton P, Felder C, Loiacono R, and Christopoulos A (2011) Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. Br J Pharmacol 162:1659-1670.
40. Valant C, Felder CC, Sexton PM, and Christopoulos A (2012) Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects. Mol Pharmacol 81:41-52.
41. Wess J (2012) Novel muscarinic receptor mutant mouse models. Handb Exp Pharmacol 208:95-117.
42. Wess J, Eglen RM, and Gautam D (2007) Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 6:721-733.
43. Wootten D, Christopoulos A, and Sexton PM (2013) Emerging paradigms in GPCR allostery: implications for drug discovery. Nat Rev Drug Discov 12:630-644.
44. Young JW, Zhou X, and Geyer MA (2010) Animal models of schizophrenia. Curr Top Behav Neurosci 4:391-433.